GHAPPcast
By Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Category: Medicine
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 151
Description
This is the official podcast of The Gastroenterology & Hepatology Advanced Practice Providers (GHAPP), an association is dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).
Through our peer-to-peer network, we seek to support their integral role in the specialty healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with gastrointestinal (GI) disorders and chronic liver disease (CLD).
| Episode | Date |
|---|---|
|
Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy
|
May 14, 2026 |
|
Medication Review: Stable PK Supporting Continuous Inflammatory Control
|
May 07, 2026 |
|
ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab
|
Apr 28, 2026 |
|
Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD
|
Apr 21, 2026 |
|
Podcast: How Do You Best Support Patients Getting Started on New MASH Treatments?
|
Apr 14, 2026 |
|
Podcast: Best Practices For Patient Identification
|
Apr 07, 2026 |
|
SubQ Solutions: Induction and Maintenance in Moderately to Severely Active CD and UC
|
Mar 31, 2026 |
|
FAQ: Treat Through VS Randomized Withdrawal Design: What's The Difference?
|
Mar 24, 2026 |
|
Medication Review: GALAXI & GRAVITI Clinical Trials & LTE Data
|
Mar 17, 2026 |
|
Podcast: Inflammation Intersection: A Rheum-Gi Dialogue
|
Mar 10, 2026 |
|
Journal Club: Risankizumab Long-Term Efficacy in Crohn’s Disease: FORTIFY Extension Results
|
Feb 24, 2026 |
|
Podcast: Upadacitinib FDA Label Update: What Clinicians Need to Know
|
Feb 17, 2026 |
|
FAQ: Biomarkers: The Non-Invasive Future of HCC Detection
|
Feb 12, 2026 |
|
FAQ: Approved Systemic Therapy in Upadacitinib’s Expanded UC and CD Indications
|
Feb 10, 2026 |
|
FAQ: What Does Clinically Inadvisable Mean in Upadacitinib’s Expanded UC and CD Indications?
|
Feb 03, 2026 |
|
FAQ: How Do You Balance Systemic and Liver Directed Therapies in Patients With MASH?
|
Jan 27, 2026 |
|
FAQ: What is the Relevance of Assessing Alcohol Consumption in Patients With MASH?
|
Jan 20, 2026 |
|
Medication Review: Resmetirom: Thyroid Hormone Receptor-β Agonism in MASH Treatment
|
Jan 13, 2026 |
|
APP Roundtable: Approach To Starting Treatments in Patients With CHB
|
Jan 07, 2026 |
|
APP Roundtable: Navigating Difficult Conversations in CHB
|
Jan 07, 2026 |
|
APP Roundtable: Addressing Co-Morbidities in CHB
|
Jan 06, 2026 |
|
FAQ: What Role Do NITs Play in Risk Stratification & Patient Selection—& Balancing Patient History?
|
Jan 06, 2026 |
|
Journal Club: Review of Focused Recommendations for the Management of MASLD
|
Dec 16, 2025 |
|
Medication Review: Resmetirom: Core Efficacy Data and Patient Selection Considerations
|
Dec 09, 2025 |
|
FAQ: What Are The Functional And Prognostic Differences Between Fibrosis F3 And F4 Patients?
|
Dec 02, 2025 |
|
The Conversation That Matters: Talking to Patients About Obesity and IMIDs
|
Dec 01, 2025 |
|
From Insight to Action: Practical Strategies to Improve Outcomes in Patients with Obesity and IMIDs
|
Nov 24, 2025 |
|
GHAPPcast: Women of Childbearing Age With IBD
|
Nov 18, 2025 |
|
The Hidden Costs: Obesity’s Role in Suboptimal Outcomes and Healthcare Burden in IMIDs
|
Nov 17, 2025 |
|
FAQ: How Do You Explain Remission To A Patient?
|
Nov 13, 2025 |
|
GHAPPcast: Mental and Sexual Health Concerns & How To Address Them For Your IBD Patient
|
Nov 11, 2025 |
|
Obesity and IMIDs: Unpacking the Epidemic and Its Far-Reaching Impacts
|
Nov 10, 2025 |
|
APP Insight: How Do You Develop a Treatment Plan for IBS-C? What Are Some Considerations?
|
Nov 04, 2025 |
|
GHAPPcast: IBS-C Therapies Explained: Helping Patients Understand Their Options
|
Oct 22, 2025 |
|
GHAPPcast: Smarter Surveillance: The Rise of Algorithms like GALAD and Their Path to Practice
|
Oct 16, 2025 |
|
FAQ: What Is the Importance of Biomarkers Such as Fecal Calprotectin and CRP?
|
Oct 14, 2025 |
|
FAQ: What Are the Next Steps When a Patient Still Has Active Disease When Taking Advanced Therapy?
|
Oct 08, 2025 |
|
APP Roundtable: Community Resources and Support Systems for CHB
|
Oct 06, 2025 |
|
APP Insight: Conducting Meaningful Conversations to Assess Therapy Impact
|
Oct 02, 2025 |
|
GHAPPcast: Decoding Diagnostics: Why Biomarker Development Phases Are Your Clinical Ally
|
Oct 01, 2025 |
|
GHAPPcast: Explaining IBS-C: Diagnosis and Communication That Builds Confidence
|
Sep 30, 2025 |
|
APP Insight: Evaluating Time to Response and Treatment Effectiveness
|
Sep 25, 2025 |
|
APP Insight: Why Is It Important to Let Patients Know There Are Different Options for Treatment?
|
Sep 23, 2025 |
|
Empowering PBC Patients: APPs’ Role in Education and Support
|
Sep 18, 2025 |
|
GHAPPcast: Payer Tutorial
|
Sep 16, 2025 |
|
APP Roundtable: Navigating Treatment Guidelines With CHB
|
Sep 05, 2025 |
|
APP Roundtable: Patient-Centric Care Approaches in PBC
|
Sep 05, 2025 |
|
APP Roundtable: Addressing Mental Health in Patients With PBC
|
Sep 05, 2025 |
|
GHAPPcast: Setting the Standard in Biomarker Validation: EDRN Example & Lessons from Liver Cancer
|
Sep 02, 2025 |
|
GHAPPcast: Navigating Difficult Conversations: Discussing prognosis and lifelong care in PBC
|
Aug 12, 2025 |
|
GHAPPcast: Collaborating Across Specialties: How APPs Can Work with Hepatologists & Other Providers in PBC Care
|
Aug 07, 2025 |
|
GHAPPcast: Managing PBC Symptoms in the Real World: Practical Tips for APPs
|
Aug 05, 2025 |
|
FAQ: What Is the Difference Between CIC and IBS-C?
|
Jul 29, 2025 |
|
GHAPPcast: Lifestyle and Nutrition Interventions for Constipation
|
Jul 24, 2025 |
|
APP Insight: Discussing Exercise as a Complement to IBS-C Treatment
|
Jul 22, 2025 |
|
GHAPPcast: Mental Health Issues and Symptoms Related to IBS-C
|
Jul 17, 2025 |
|
FAQ: What Is the Significance of Alarm Symptoms Including Pathophysiology?
|
Jul 15, 2025 |
|
APP Roundtable: Future Directions in CHB Research
|
Jul 10, 2025 |
|
APP Roundtable: Navigating Treatment Guidelines in CHB
|
Jul 10, 2025 |
|
APP Insight: Provide Diagnostic Tips for IBS-C
|
Jul 10, 2025 |
|
APP Insight: Using the Bristol Stool Scale to Measure Response to Treatment
|
Jul 08, 2025 |
|
APP Roundtable: Challenges in Diagnosing CHB
|
Jul 02, 2025 |
|
APP Roundtable: Future Directions in PBC Research
|
Jul 02, 2025 |
|
APP Roundtable: Multidisciplinary Care Models in PBC Management
|
Jul 02, 2025 |
|
APP Roundtable: PBC Patient Perspectives & Advocacy
|
Jul 02, 2025 |
|
FAQ: What Are the Main Causes of IBS, and How Does the Disease Progress Over Time?
|
Jul 01, 2025 |
|
KOL Conversation: Setting Expectations When Initiating New Therapy
|
Jun 10, 2025 |
|
KOL Conversation: Diagnosing IBS With Confidence
|
Jun 05, 2025 |
|
KOL Conversation: Diagnosing EPI and Managing With The Appropriate PERT Dosing
|
Jun 03, 2025 |
|
KOL Conversation: Implementing the IBS Guidelines
|
May 29, 2025 |
|
GHAPPcast: The Clinical Utility of Guselkumab in CD
|
Mar 31, 2025 |
|
GHAPPcast: Not Responding to UDCA in the First Few Months, Need to Move on to Second-Line Therapy
|
Mar 28, 2025 |
|
GHAPPcast: Need for Earlier Evaluation of UDCA Response, Need for Earlier Consideration of Second-Line Therapy
|
Mar 28, 2025 |
|
GHAPPcast: Importance of Understanding Impact on Disease Outcomes: Progression to Fibrosis and Cirrhosis
|
Mar 28, 2025 |
|
GHAPPcast: Building a Sense of Urgency for PBC Patient Evaluation/Monitoring
|
Mar 28, 2025 |
|
GHAPPcast: Need for Clinicians to Better Understand The "Area Under the Curve" in Non-Response to UDCA
|
Mar 28, 2025 |
|
GHAPPcast: Unable to Differentiate/Identify Between Slow & Fast Progressors - Need to Manage More Aggressively
|
Mar 28, 2025 |
|
GHAPPcast: Better Understanding of PBC Patients Overall Liver Health and Managing Patients Holistically
|
Mar 28, 2025 |
|
GHAPPcast: Biomarkers Beyond ALP to Monitor for Measuring PBC UDCA Response to Therapy and Disease Progression
|
Mar 28, 2025 |
|
Journal Club: Week 48 Efficacy of Guselkumab vs. Ustekinumab in Crohn’s Disease: Insights from GALAXI 2 & 3
|
Mar 26, 2025 |
|
GHAPPcast: Simplifying Access: Evolving Drug Distribution Channels
|
Mar 25, 2025 |
|
GHAPPcast: Simplifying Access: Prior Authorization Part 2
|
Mar 25, 2025 |
|
GHAPPcast: Simplifying Access: Prior Authorization Part 1
|
Mar 25, 2025 |
|
Journal Club: Efficacy & Safety of Subcutaneous Guselkumab: 48-Week Results from the Phase 3 GRAVITI Study
|
Mar 18, 2025 |
|
GHAPPcast: The Clinical Utility of Guselkumab in UC
|
Mar 11, 2025 |
|
KOL: What Are the Most Critical Updates in Cirrhosis Research That Clinicians Should Be Aware Of?
|
Mar 06, 2025 |
|
KOL: How Can Healthcare Professionals Improve Patient Outcomes in Those with Cirrhosis?
|
Mar 04, 2025 |
|
Journal Club: Efficacy and Safety of Guselkumab in Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results
|
Feb 27, 2025 |
|
FAQ: How does the guselkumab data align with the STRIDE II guidelines?
|
Feb 25, 2025 |
|
Medication Review: What are guselkumab's other FDA indications and how might that affect patient care?
|
Feb 20, 2025 |
|
KOL Interview: Can You Discuss Any Recent Breakthroughs in the Management of Cirrhosis?
|
Feb 19, 2025 |
|
FAQ: What should patients know about living with cirrhosis?
|
Feb 17, 2025 |
|
FAQ: What are predictive risk factors for disease severity in CD and UC?
|
Feb 13, 2025 |
|
FAQ: What lifestyle changes are essential for managing cirrhosis effectively?
|
Feb 12, 2025 |
|
Journal Club: Guselkumab Efficacy & Safety in Moderate to Severe CD-GALAXI 2 & 3 Results
|
Feb 11, 2025 |
|
FAQ: How Can You Support a Shared Decision-Making Process With the Patient?
|
Feb 10, 2025 |
|
Medication Review: What is the efficacy of guselkumab in ulcerative colitis and Crohn's disease?
|
Feb 06, 2025 |
|
FAQ: How can physicians better care for patients with cirrhosis?
|
Feb 05, 2025 |
|
Medication Review: What is the safety profile of guselkumab in ulcerative colitis and Crohn's disease?
|
Feb 04, 2025 |
|
Journal Club: Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study
|
Jan 30, 2025 |
|
GHAPPcast Part 3: Provider & Patient Support
|
Jan 29, 2025 |
|
FAQ: Is there a correlation of myeloid cells expressing CD64 and endoscopy disease severity?
|
Jan 28, 2025 |
|
GHAPPcast Part 2: Diagnosis and Management
|
Jan 24, 2025 |
|
FAQ: Why is binding CD64+ important when discussing IL23 directed therapy?
|
Jan 23, 2025 |
|
GHAPPcast Part 1: Understanding Chronic Liver Disease and Cirrhosis
|
Jan 22, 2025 |
|
Medication Review: How is guselkumab dosed in IBD?
|
Jan 21, 2025 |
|
GHAPPcast: CD64+ Binding: Description, Relevance, and Potential Clinical Implications
|
Jan 16, 2025 |
|
FAQ: Provide immunologic rationale for IL23 directed therapy in IBD(+ general overview of Guselkumab MOA)
|
Jan 14, 2025 |
|
Journal Club: Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis
|
Jan 09, 2025 |
|
Medication Review: What is non-responder imputation and how is it utilized in clinical trials?
|
Jan 07, 2025 |
|
FAQ: What is the role of IL23/IL17 axis in IBD
|
Dec 17, 2024 |
|
FAQ: Describe the IL23/IL17 axis
|
Dec 12, 2024 |
|
GHAPPcast: The IL23/IL17 Cascade and Implications in the Pathogenesis of IBD
|
Dec 12, 2024 |
|
Medication Review: Describe the mechanism of action of guselkumab
|
Dec 05, 2024 |
|
FAQ: Define, compare, and contrast humoral and cell-mediated immunity.
|
Dec 04, 2024 |
|
GHAPPcast: CSID in Adults: Clinical Pearls & the Patient Journey
|
Nov 14, 2024 |
|
GHAPP PBC Podcast Series Part 1: Prevalence, Awareness and Identification of PBC
|
Oct 18, 2024 |
|
GHAPP PBC Podcast Series Part 2: New Therapeutics In The PBC Space
|
Oct 18, 2024 |
|
GHAPP PBC Podcast Series Part 3: The Key Highlights of PBC at the GHAPP Conference 2024
|
Oct 18, 2024 |
|
KOL Conversation: A New Treatment Option
|
Oct 15, 2024 |
|
KOL Conversation: New & Emerging Treatment Considerations for PBC & PBC Pruritus
|
Oct 15, 2024 |
|
Journal Club: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
|
Oct 03, 2024 |
|
FAQ: What is MASH?
|
Oct 03, 2024 |
|
FAQ: What are the consequences of NASH going untreated?
|
Oct 03, 2024 |
|
FAQ: How is MASH severity staged? What would an ideal MASH NIT algorithm look like?
|
Oct 03, 2024 |
|
Medication Review Video Module: What is Resmetirom and how does it work to treat MASH?
|
Oct 03, 2024 |
|
Medication Review: What is the clinical profile of Resmetirom, including dosing schedules?
|
Oct 03, 2024 |
|
GHAPPcast: Recognizing the Severity of MASH
|
Oct 03, 2024 |
|
FAQ: Best practices to accelerate the time to finding the right therapy for your patients with IBS-C?
|
Sep 18, 2024 |
|
FAQ: What does it mean for a biosimilar to be interchangeable and why is that important?
|
Sep 17, 2024 |
|
FAQ: What resources do you use to understand the latest approaches to managing IBS-C patients?
|
Sep 17, 2024 |
|
FAQ: What are some best practices in determining clinically meaningful “response” to therapy for IBS-C patients?
|
Sep 17, 2024 |
|
GHAPPcast: Navigating IBS: Pathophysiology, Neuromodulators, and Patient-Centered Care
|
Sep 17, 2024 |
|
GHAPPcast: Biosimilars and the Patient Perspective
|
Sep 17, 2024 |
|
GHAPPcast: Mastering IBS-C: Diagnostic Strategies, Differentiation, and Management.
|
Sep 10, 2024 |
|
FAQ: What is the Difference Between Biosimilars and Generics?
|
Sep 04, 2024 |
|
FAQ: What Role Does a New Mechanism of Action Play in Your Prescribing Decisions of IBS-C Therapy?
|
Aug 26, 2024 |
|
GHAPPcast: Biosimilars Unveiled: Empowering APPs for Better Patient Conversations
|
Aug 21, 2024 |
|
CLDF/GHAPP Roundtable Podcast Series: MASH with Nadege Gunn, MD, Elizabeth Goacher, PA, and Ann Moore, FNP
|
Aug 05, 2024 |
|
Discussing Biosimilars With Patients
|
Dec 13, 2023 |
|
The Nocebo Effect
|
Dec 08, 2023 |
|
The Practical Use of Biosimilars in Gastroenterology APP Practice
|
Nov 08, 2023 |
|
The Practical Use of Biosimilars in Rheumatology APP Practice
|
Oct 30, 2023 |
|
The Benefits of Biosimilars
|
Oct 11, 2023 |
|
Managed Care and Biosimilars
|
Oct 03, 2023 |
|
Interchangeability & Switching of Biosimilars
|
Sep 15, 2023 |
|
Biosimilar Extrapolation
|
Aug 23, 2023 |
|
The Difference Between Biosimilars & Generic Drugs
|
Aug 08, 2023 |
|
The Regulatory Pathway to Biosimilar Approval
|
Jul 25, 2023 |
|
Development of Biosimilars
|
Jul 13, 2023 |
|
Biosimilars Series: What Are Biosimilars?
|
Jun 14, 2023 |